Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence
Pharmacology · 2021 · 106 (3-4) · 143-153
DOI: 10.1159/000510343 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology, online erschienen am 23.09.2020. Verfasst von Philip C Müller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hirslanden Klinik Beau-Site, Bern, Switzerland. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
At the time of diagnosis, only about 20% of patients with pancreatic ductal adenocarcinoma (PDAC) have resectable disease. PDAC treatment necessitates a multidisciplinary approach, and adjuvant chemotherapy after upfront resection is an established means of preventing recurrence. Neoadjuvant chemotherapy (NAT), originally introduced to downstage tumor size, is nowadays more frequently used for selection of patients with favorable tumor biology and to control potential micrometastases. While NAT is routinely applied in locally advanced (LA) PDAC, there is increasing evidence demonstrating benefits of NAT in borderline resectable (BR) PDAC. The concept of NAT has recently been tested in resectable PDAC, but to date NAT has been restricted to clinical trials, as the data are limited and no clear benefits have yet been shown in this patient group. This review summarizes the current evidence for NAT in resectable, BR, and LA PDAC, with a focus on high-level evidence and randomized controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Hirslanden Klinik Beau-Site, Bern, Switzerland.
- Swiss Pancreas Center, Hirslanden Klinik Beau-Site, Bern, Switzerland.
- Department of Pediatric Surgery, University Hospital Bern, University of Bern, Bern, Switzerland.
- Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Gastroenterology, Hirslanden Klinik Beau-Site, Bern, Switzerland.
- Department of Oncology, Hirslanden Klinik Beau-Site, Bern, Switzerland.
Zitieren
APA
Müller, P. C., Frey, M. C., Ruzza, C. M., Nickel, F., Jost, C., Gwerder, C., Hackert, T., Z'graggen, K., & Kessler, U. (2021). Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. Pharmacology, 106(3-4), 143-153. https://doi.org/10.1159/000510343
Vancouver
Müller PC, Frey MC, Ruzza CM, Nickel F, Jost C, Gwerder C, et al. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. Pharmacology. 2021;106(3-4):143-153. doi:10.1159/000510343
BibTeX
@article{Mller2021,
author = {Müller, Philip C and Frey, Michael C and Ruzza, Claudio M and Nickel, Felix and Jost, Christian and Gwerder, Christoph and Hackert, Thilo and Z'graggen, Kaspar and Kessler, Ulf},
title = {Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence},
journal = {Pharmacology},
year = {2021},
volume = {106},
number = {3-4},
pages = {143--153},
doi = {10.1159/000510343}
}
EUVIMED